Skip to content

Regeneron Pharmaceuticals

US · REGN #285 by market cap Listed 1970
742.12 +3.40 +0.46%
Live - 5344 symbols - heartbeat 548s ago · 2026-10-08 05:13
Pre-market 742.00 -0.02%
After-hours 742.12 0.00%
Overnight 741.93 -0.03%
Market cap
76.40B
P/B
2.41
EPS
41.48
Reader sentiment Are you bullish or bearish on REGN?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Near fair value
499.38 fair value ≈ 752.12 1,004.85
  • Implied fair-value range of 499.38-1,004.85, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -1.3% below the average-multiple fair value of 752.12.

Valuation each multiple against its own 5-year range

P/B ratio 2.36 Cheap vs history 17th percentile
5-year average 3.26 · #248 of 514 in Biotechnology
P/E ratio 17.98 In line with history 51st percentile
5-year average 18.13 · forward 12.90 · #45 of 73 in Biotechnology
P/S ratio 4.81 Cheap vs history 27th percentile
5-year average 5.90 · forward 4.09 · #104 of 388 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%
BeiGene (ONC) 41.39B 64.43 8.00 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value736.52 Economic moatNarrow UncertaintyMedium

Trading 0.8% above Morningstar's fair value estimate.

Fair value

Regeneron Pharmaceuticals Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 1% discount to our quantitative fair value estimate of $736.52 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-10-08 05:13:24 · For reference only, not investment advice and not tailored to your situation.